mexiletine
Orphan DrugFDA Approved
Description
Mexiletine is a sodium channel blocker originally developed as an antiarrhythmic agent. It has been repurposed for treating neuropathic pain and primary erythermalgia by stabilizing hyperexcitable nerve membranes. It reduces the frequency and severity of painful burning episodes in erythermalgia patients.
Indications & Therapeutic Use
primary erythermalgia, neuropathic pain, myotonia, ventricular arrhythmias
Linked Diseases:
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
mexiletine
| Generic Name | mexiletine |
| Brands | 1 brand available |
| Active Ingredient | mexiletine hydrochloride |
| Drug Class | primary erythermalgia |
| Manufacturer | Lupin Pharmaceuticals |
| Dosage Forms | oral capsule 150mg, 200mg, 250mg |
| Medical Code | C01BB02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02045667 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes